DDrare: Database of Drug Development for Rare Diseases

Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2% sodium chondroitin sulfate; 5% lidocaine/5 mg/ml 0.02% estradiol compound cream; AGN 203818; AQX-1125; AQX-1125 100 mg; AQX-1125 200 mg; ASP3652; ASP6294; Adalimumab; Alkalinized Lidocaine-Heparin; Amitriptyline; BOTOX 200U in normal saline; Bladder Instillations; Bladder instillation WITH triamcinolone acetonide; Bladder instillation WITHOUT triamcinolone acetonide; Bladder instillation with heparin/ lidocaine; Botox; Botulinum toxin A; Buckwheat; Bupivacaine; CICLOSPORIN; Cannabidiol; Cannabidiol vaginal suppository; Capsaicin; Certolizumab pegol; Chondroitin sulfate; Ciclosporin; Ciklosporin; Combination Product: Hyperbaric Oxygen Therapy-; Cyclosporine; DMSO; DMSO cocktail; Device: Intermittent Exposure to Oxygen via Oro-Nasal Mask; Device: interferential current; Dexmedetomidine; Dimethyl sulfoxide; ERB-041; Estradiol; Fospropofol; Fospropofol (Lusedra®) 10; Fospropofol (Lusedra®) 12; Fospropofol (Lusedra®) 6.5; Fremanezumab; Gefapixant; Glycine; Gralise; Heparin; Heparin & Alkalinized Lidocaine Bladder Instillation; Hyaluronic Acid and Chondroitin Sulfate; Hyaluronic acid; Hyaluronic acid/chondroitin sulfate; Hydrogen; IC Cocktail; IPD® (Japanese tradename); IPD® (suplatast tosilate); Intravesical onabotulinumtoxinA injection; JNJ-42160443; KRP-116D; Ketorolac; Ketorolac Tromethamine; LP-08 20mg; LP-08 80mg; LiRIS 400 mg; LiRIS low dose and LiRIS high dose; LiRIS®; LiRIS® 400 mg; Lidocaine; Lidocaine Releasing Intravesical System - LiRIS®; Liposome encapsulated BoNT-A; Liposomes; Low-dose naltrexone; MMF; MN-001; MN-001 BID; MR-MC-01; Metoprolol; Metoprolol Tartrate Oral Tablet; Mirabegron; Mycofenolate Mofetil (MMF); Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; NALOXONE HYDROCHLORIDE; Naloxone; Naltrexone; Normal Saline; Normal saline; Normal saline instillation; Nortriptyline; OXN 10/5 mg PR; OXN 20/10 mg PR; OXN 5/2.5 mg PR; OXYCODONE HYDROCHLORIDE; Omalizumab; Onabotulinum Toxin A; Onabotulinumtoxin A; OnabotulinumtoxinA; Other: Hyperbaric Oxygen Therapy; Other: Normal Saline; Other: Saline as a nasal spray; Other: inactive drug; Other: normal saline; Oxycodone; Oxycodone naloxone prolonged release tablets; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Oxygen; Oxytocin; PD 0299685; PD 0299685 at 15mg BID; PD 0299685 at 30mg BID; PD-0299685; PF-04383119; Pentosan polysulfate; Pentosan polysulfate sodium 100 mg; Placebo; Platelet enriched plasma; Platelet-Rich Plasma; Procedure: Pelvic Floor Physical Therapy; Procedure: Sham Cystoscopy Procedure; Procedure: Urodynamic study; Procedure: injections on posterior bladder wall excluding the trigone; Procedure: injections upper aspect of trigone of urinary bladder; Prograf; Propiverine; Propiverine Hydrochloride; RIMSO 50; RN624, RI624; Rimso 50; SANDIMMUN; SI-722; Sandimmun Neoral; Sildenafil; Sulfate; Suplatast tosilate; TACROLIMUS; TTI-1612; Tacrolimus; Tanezumab; Targinact 10 mg/5 mg prolonged-release tablets; Targinact 20mg/10 mg prolonged-release tablets; Targinact 5mg/2.5 mg prolonged-release tablets; Tramadol; Triamcinolone; Tromethamine; URG101; Water; YM672; YM672 (IPD®)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03463499 (ClinicalTrials.gov)	September 22, 2017	25/2/2018	The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients	The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients	Interstitial Cystitis	Drug: Hyaluronic Acid and Chondroitin Sulfate	Samsung Medical Center	NULL	Active, not recruiting	20 Years	N/A	All	62	N/A	Korea, Republic of
2	NCT01813565 (ClinicalTrials.gov)	March 20, 2013	11/3/2013	The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.	The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.	Interstitial Cystitis	Drug: Hyaluronic acid /chondroitin sulfate	Asan Medical Center	NULL	Terminated	20 Years	N/A	All	15	N/A	Korea, Republic of
3	EUCTR2010-021556-25-IT (EUCTR)	24/02/2011	04/11/2010	Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS)AscoltaTrascrizione foneticaDizionario - Visualizza dizionario dettagliato - IBSA 01-2010	Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS)AscoltaTrascrizione foneticaDizionario - Visualizza dizionario dettagliato - IBSA 01-2010	Interstitial Cystitis MedDRA version: 9.1;Level: HLGT;Classification code 10018188	Trade Name: RIMSO 50 INN or Proposed INN: Dimethyl sulfoxide	IBSA	NULL	Not Recruiting			Female: yes Male: no		Phase 3	Italy
4	NCT00919113 (ClinicalTrials.gov)	July 2009	11/6/2009	Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome	A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Effectiveness and Safety of Uracyst® Compared to Inactive Control in Subjects With Interstitial Cystitis/Painful Bladder Syndrome	Interstitial Cystitis;Painful Bladder Syndrome	Drug: 2% sodium chondroitin sulfate;Drug: Placebo	Watson Pharmaceuticals	NULL	Completed	18 Years	N/A	Female	98	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03463499
(ClinicalTrials.gov)

September 22, 2017

25/2/2018

The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients

Interstitial Cystitis

Drug: Hyaluronic Acid and Chondroitin Sulfate

Samsung Medical Center

NULL

Active, not recruiting

20 Years

N/A

All

N/A

Korea, Republic of

NCT01813565
(ClinicalTrials.gov)

March 20, 2013

11/3/2013

The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.

Interstitial Cystitis

Drug: Hyaluronic acid /chondroitin sulfate

Asan Medical Center

NULL

Terminated

20 Years

N/A

All

N/A

Korea, Republic of

EUCTR2010-021556-25-IT
(EUCTR)

24/02/2011

04/11/2010

Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS)AscoltaTrascrizione foneticaDizionario - Visualizza dizionario dettagliato - IBSA 01-2010

Interstitial Cystitis
MedDRA version: 9.1;Level: HLGT;Classification code 10018188

Trade Name: RIMSO 50
INN or Proposed INN: Dimethyl sulfoxide

IBSA

NULL

Not Recruiting

Female: yes
Male: no

Phase 3

Italy

NCT00919113
(ClinicalTrials.gov)

July 2009

11/6/2009

Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome

A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Effectiveness and Safety of Uracyst® Compared to Inactive Control in Subjects With Interstitial Cystitis/Painful Bladder Syndrome

Interstitial Cystitis;Painful Bladder Syndrome

Drug: 2% sodium chondroitin sulfate;Drug: Placebo

Watson Pharmaceuticals

NULL

Completed

18 Years

N/A

Female

Phase 2

United States